Durham Company Sets Terms Of $69M IPO

This is source I found from another site, main source you can find in last paragraph

Chimerix, a biopharmaceutical company developing oral antiviral therapeutics for CMV, announced terms for its IPO on Monday. The Durham, NC-based company plans to raise $85 million by offering 6.1 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Chimerix would command a market value of $325 million.

Chimerix, which booked $34 million in sales for the 12 months ended 12/31/2012, plans to list on the NASDAQ under the symbol CMRX. Chimerix initially filed confidentially on 1/30/2013. Morgan Stanley and Cowen & Company are the joint bookrunners on the deal.

This is source I found from another site, main source you can find in last paragraph

Source : http://www.nasdaq.com/article/biotech-company-chimerix-sets-terms-for-85-million-ipo-cm232282

line

mercantilism

Biotech company Chimerix sets terms for $85 million IPO
Patheon sets terms of IPO
Twitter IPO: $1B offering on $253M of revenue and $69M loss in first half of 2013
Testing services provider Quintiles sets IPO range at $36-$40/shr
Dova and Novartis-backed Aileron file for new IPOs as biotech offerings tick up
Personalized immunotherapy could signal first combination treatment for renal cell carcinoma patients
In a Subprime Bubble for Used Cars, Borrowers Pay Sky-High Rates
Cree Reports Financial Results for the Fourth Quarter and Fiscal Year 2017
Evoke Pharma Secures $4.5M Loan Facility With Square 1 Bank